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ABSTRACT
Objectives To report clinician- perceived changes to 
cancer service delivery in response to COVID-19.
Design Multidisciplinary Australasian cancer clinician 
survey in collaboration with the European Society of 
Medical Oncology.
Setting Between May and June 2020 clinicians from 70 
countries were surveyed; majority from Europe (n=196; 
39%) with 1846 COVID-19 cases per million people, 
Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 
267/236 per million and Asia (n=75; 15%) with 121 per 
million at time of survey distribution.
Participants Medical oncologists (n=372; 74%), radiation 
oncologists (n=91; 18%) and surgical oncologists (n=38; 
8%).
Results Eighty- nine per cent of clinicians reported 
altering clinical practices; more commonly among those 
with versus without patients diagnosed with COVID-19 
(n=142; 93% vs n=225; 86%, p=0.03) but regardless of 
community transmission levels (p=0.26). More European 
clinicians (n=111; 66.1%) had treated patients diagnosed 
with COVID-19 compared with Asia (n=20; 27.8%) and 
AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 
71.4%) reported concerns that reduced access to standard 
treatments during the pandemic would negatively impact 
patient survival. The reported proportion of consultations 
using telehealth increased by 7.7- fold, with 25.1% 
(n=108) of clinicians concerned that patient survival 
would be worse due to this increase. Clinicians reviewed a 
median of 10 fewer outpatients/week (including non- face 
to face) compared with prior to the pandemic, translating 
to 5010 fewer specialist oncology visits per week among 
the surveyed group. Mental health was negatively 
impacted for 52.6% (n=190) of clinicians.
Conclusion Clinicians reported widespread changes 
to oncology services, in regions of both high and low 
COVID-19 case numbers. Clinician concerns of potential 
negative impacts on patient outcomes warrant objective 
assessment, with system and policy implications for 
healthcare delivery at large.
INTRODUCTION
Patients with cancer are at significantly 
increased risk of morbidity and death 
from COVID-19, with mortality estimates 
ranging from 11% to 40.5% across different 
studies.1–6 This large range likely reflects the 
heterogeneity of these studies, with some 
including patients with inactive cancer versus 
only active cancer and some including only 
hospitalised patients. Although it is clear 
that COVID-19- related outcomes are poor 
in patients with cancer, the impact of anti-
cancer therapy on these outcomes remains 
contentious. Many studies have reported that 
recent use of anticancer therapy may worsen 
COVID-19- related outcomes.2 3 7 8 One of the 
largest of these studies, from the COVID-19 
and Cancer Consortium, reported that 
recent use of anticancer therapy, including 
chemotherapy- immunotherapy and targeted 
therapy (anti- CD20 in particular), was asso-
ciated with increased mortality.8 However, 
other studies have found that recent use of 
Key questions
What is already known about this subject?
 ► The COVID-19 pandemic is impacting cancer service 
delivery.
What does this study add?
 ► Eighty- nine per cent of surveyed oncology clinicians 
report altering cancer management.
 ► The surveyed group report 5010 fewer patient visits/
week during the pandemic.
 ► Clinicians report a 7.7- fold increase in the propor-
tion of consultations using telehealth.
 ► Twenty- five per cent of clinicians report concerns 
that increased telehealth could lead to worsened 
patient survival.
How might this impact on clinical practice?
 ► Reduced patient presentations and alterations to 
standard treatment pathways may result in in-
creased cancer- related mortality.
 ► The public should be encouraged to present early 
with cancer- related signs or symptoms.
 ► Clinicians’ concerns regarding telehealth require 
further exploration.
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anticancer therapy was not independently associated 
with mortality.9 This ambiguity contributes to addi-
tional uncertainty in decision- making regarding cancer 
treatments for both patients and clinicians during the 
pandemic period.
Although understanding of COVID-19 is rapidly 
evolving, it was clear from early on that strains on health 
infrastructures and increased risk of mortality in patients 
with cancer during the pandemic had implications on 
the delivery of cancer health services. In accordance 
with this, multiple institutional, national and interna-
tional guidelines were released to inform the practice 
of clinicians caring for people with cancer during the 
COVID-19 pandemic. Recommended measures included 
reducing hospital visits by delaying treatments, reducing 
the frequency of therapy and the preferential use of oral 
agents.10–12
As clinicians and policymakers grapple with the direct 
impact of COVID-19 on patients and healthcare systems, 
the indirect impact on patients with chronic illness and 
non- communicable disease, such as cancer, is of increasing 
concern.13 In many countries, diagnostic pathways have 
been disrupted by a multitude of factors, including 
closure or downscaling of cancer screening programmes 
and changes to health- seeking behaviours.14 15 The impact 
of delayed referrals and presentations is unknown, but 
mathematical modelling indicates significant impacts 
in terms of excess cancer- related deaths16 and impacts 
to healthcare budgets.17 Both the direct and indirect 
impacts of COVID-19 on patients with cancer and health-
care systems are alarming and further work is required to 
understand specific changes in cancer management and 




The survey aimed to determine clinicians’ perspec-
tives on cancer service delivery during the COVID-19 
pandemic. Target participants were medical oncologists, 
radiation oncologists and surgical oncologists or trainees 
in these fields. The survey was designed by the project 
team with refinement and piloting through consulta-
tion with an expert panel of clinicians. The survey was 
administered in English language only and consisted of 
23 questions regarding clinician demographics, changes 
to cancer management and service delivery and factors 
influencing these changes (online supplemental file 1). 
The survey distributed by Australian and European soci-
eties was identical but for the terminology used in ques-
tions 17.2/18.2 relating to categories of surgical urgency. 
Responses were a mix of qualitative and quantitative data. 
Informed consent was implied from participants’ deci-
sion to undertake the survey. Responses were anonymous 
and data were non-identifiable.
Survey distribution
The online survey, open between 4 May and 19 June 
2020, was distributed via email hyperlink from profes-
sional societies within Australia (AUS) and Europe 
(non- random sampling). These organisations were Clin-
ical Oncology Society of Australia, European Society of 
Medical Oncology (ESMO), Medical Oncology Group 
of Australia, Royal Australian College of Surgeons and 
Royal Australian and New Zealand College of Radiolo-
gists (RANZCR). The hyperlink was also published in the 
online newsletter of ESMO and RANZCR. Selected partic-
ipants with leadership positions in their societies were 
also invited to participate via snowball sampling.
Data analysis
Descriptive statistics were used to analyse and report 
outcomes from survey response data. Quantitative data 
are reported using mean, standard deviation, median 
(and quartiles 1 and 3 where of particular importance). 
Qualitative data are reported using absolute number of 
participants in addition to the percentage of participants 
who selected a given response. The denominator used 
to calculate the percentage reflects the total number of 
clinicians answering that specific question. The number 
of participants who commenced the survey but did not 
complete a given question is reported as ‘N- miss’. Partic-
ipants who completed less than 3% of the survey were 
excluded from analysis (n=2). Changes in percentage 
telehealth use are reported as x- fold increase, calcu-
lated by dividing the mean percentage use during the 
pandemic by the mean percentage use prior to the 
pandemic. P values were calculated using the Kruskal- 
Wallis test for numerical data and the χ2 test for categor-
ical data. Geographical location of practice was collected 
as country but is reported by major area (Europe, AUS/
New Zealand (NZ), Asia and ‘Other’ for countries outside 
of these regions, which collectively accounted for 8.4% 
of responses). ‘Australia/New Zealand’ was used instead 
of ‘Oceania’ as there were no other responding coun-




Internationally, 501 clinicians took the survey. Most partic-
ipants were medical oncologists (n=372; 74.3%), 18.2% 
(n=91) were radiation oncologists and 7.6% (n=38) were 
surgical oncologists. Clinician demographics are summa-
rized in online supplemental table 1. The mean age was 44 
years, 50.3% (n=252) were female and 48.5% (n=243) were 
male. Seventy countries were represented, with each indi-
vidual country accounting for <5% of participants except 
for AUS (n=168; 33.5%), Italy (n=34; 6.8%), Spain (n=28; 
5.6%) and India (n=25; 5.0%) (online supplemental table 
2). Participants most commonly worked at metropolitan 
general hospitals (n=208; 41.6%) and metropolitan special-
ised cancer centres (n=165; 33.0%). Nearly a quarter (n=120; 
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24.0%) worked in regional settings. Level of clinician experi-
ence varied with 21.2% (n=106) participants being trainees 
and 42.5% (n=213) having worked as consultants for 10 
years or more. The date of survey completion ranged from 
4 May 2020 to 15 June 2020; cumulative COVID-19 cases 
per million people on the first and last days of the survey 
increased from 267 to 290 in AUS (relative change +9%), 
236 to 240 in NZ (relative change +2%), 1846 to 2969 in 
Europe (relative change +59%) and 121 to 386 in Asia (rela-
tive change +218%).18
Clinicians with patients diagnosed with COVID-19
The percentage of clinicians who reported having 
had patients diagnosed with/die from COVID-19 was 
66.1%/31.5% in Europe, 27.8%/8.3% in Asia and 
4.8%/1.2% in AUS/NZ. Clinicians who had a patient 
diagnosed with COVID-19 were more likely to alter their 
practice during the pandemic compared with clinicians 
who had no patients diagnosed with COVID-19 (n=142; 
93.4% vs n=225; 86.4%, p=0.03).
Changes to outpatient consultations
During the pandemic, clinicians reported seeing a median 
of 10 (Q1=−20, Q3=0) fewer outpatients/week (including 
non- face- to- face modalities). This correlates to 5010 fewer 
patients being reviewed by the surveyed oncology clini-
cians each week. This change was smaller in AUS (median 
4 fewer/week) compared with Asia (median 20 fewer/
week) and Europe (median 10 fewer/week) (p<0.001). The 
percentage of outpatient consultations conducted by tele-
health increased by 11.8- fold in AUS/NZ, 7.2- fold in Europe 
and 3.8- fold in Asia (figure 1).
Factors influencing clinicians to alter/not to alter practice
Most clinicians (n=397; 88.8%) reported altering cancer 
management or the delivery of cancer services due to the 
COVID-19 pandemic, with similar rates across Europe 
(n=152; 90.5%), AUS/NZ (n=142; 85.0%) and Asia (n=66; 
91.7%) despite disparities in COVID-19 case numbers 
(p=0.26). Patient and system factors influencing clinicians to 
alter practice are shown in table 1. The patient and system 
factors influencing the largest percentage of clinicians across 
all regions were (1) presence of respiratory comorbidities 
(n=293; 74.7%, p=0.20) and (2) institutional guidelines 
(n=275; 70.2%, p=0.06). There were regional differences 
in proportion influenced by certain factors, for example, 
(1) concern about overwhelming the healthcare system by 
Figure 1 Outpatient consultants conducted via telehealth (broadly defined) before and during COVID-19.
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41.5% (n=27) in Asia, 40.7% (n=57) in AUS/NZ and 26.0% 
(n=39) in Europe (p=0.03) and (2) inadequate staff by 
44.6% (n=29) in Asia, 32.1% (n=45) in AUS/NZ and 15.3% 
(n=23) in Europe (p<0.001).
Fifty participants (11.2%) reported not altering cancer 
management or the delivery of cancer services due to 
COVID-19 (n=34; 10.3% of medical oncologists, n=9; 
10.7% of radiation oncologists and n=7; 21.9% of surgical 
oncologists). These clinicians were from AUS (n=25; 
50.0%), Europe (n=16; 32.0%) and Asia (n=6; 12.0%) and 
most (n=40; 80.0%) had not had a patient diagnosed with 
COVID-19. For the 50 participants not altering practice, 
factors influencing this decision included (1) belief that 
patients should have access to standard of care treatment 
despite the risk of COVID-19 (n=33; 66.0%), (2) belief that 
no change to cancer management was required (n=16; 
32.0%), and (3) feeling they did not have enough evidence 
or guidelines to change cancer management because of 
COVID-19 (n=9; 18.0%).
Changes to patient management due to COVID-19: medical 
oncologists
In the curative setting, some medical oncologists reported 
being less likely to prescribe adjuvant systemic therapy (n=53; 
18.2%) or neoadjuvant systemic therapy (n=39; 13.4%) 
(figure 2A). In the palliative setting, the majority of medical 
oncologists reported altering management, with 60.1% 
(n=175) being more likely to alter their choice of systemic 
therapy, 44.0% (n=128) being more likely to prescribe a 
reduced dose, 45.0% (n=131) being more likely to delay 
starting treatment and 44.3% (n=129) being more likely to 
stop systemic treatment (figure 2B). A greater proportion of 
medical oncologists in AUS/NZ reported being more likely 
to stop treatment (n=49; 63.6%), compared with those in 
Europe (n=52; 38.8%) and Asia (n=18; 37.5%) (p<0.001). 
Clinicians also reported being more likely to add granu-
locyte colony- stimulating factor in both curative settings 
(n=167; 57.4%) and palliative settings (n=116; 39.9%).
Changes to patient management due to COVID-19: radiation 
oncologists
Most radiation oncologists reported being more likely to alter 
the fractionation of radiotherapy in both the curative setting 
(n=61; 82.4%) and the palliative setting (n=58; 78.4%). Some 
radiation oncologists (n=16; 21.6%) reported being less likely 
to prescribe adjuvant radiotherapy and 54.1% (n=40) were 
more likely to delay starting adjuvant radiotherapy (figure 3A). 
Few (n=2; 2.7%) were less likely to prescribe definitive radio-
therapy. Almost one- third (n=23; 31.1%) reported being less 
likely to prescribe palliative radiotherapy (figure 3B).
Changes to patient management due to COVID-19: surgical 
oncologists
Twenty- five surgeons (65.8%) responded to questions about 
changes in cancer management during the pandemic. Of 
these, 40% (n=10) reported delaying surgery and 12% 
(n=3) reported deciding not to operate in the urgent 
elective setting. In the non- urgent elective setting, 80% 
(n=20) reported delaying surgery and 32% (n=8) reported 
deciding not to operate.
Predicted impact of changes to patient management and 
oncology service delivery
Most participants (n=313; 72.8%) reported increasing 
non- face- to- face consultation modalities would not impact 










N- miss 46 48 10 5 109
Age 71.3% 72.9% 83.1% 73.0% 74% 0.327
Performance status 73.3 60.0% 83.1% 75.7% 70.4% 0.004
Presence of respiratory comorbidities 70.7% 74.3% 84.6% 75.7% 74.7% 0.194
Presence of non- respiratory comorbidities 30.0% 44.3% 49.2% 35.1% 38.8% 0.020
Patient’s preference 55.3% 72.9% 70.8% 54.1% 64.0% 0.006
Patient’s social situations put them at higher risk of 
COVID-19
48.0% 44.3% 75.4% 56.8% 52.0% <0.001
Active COVID-19 infection 72.7% 46.4% 63.1% 62.2% 60.7% <0.001
Other patient factor 1.3% 17.1% 7.7% 5.4% 8.4% <0.001
Institutional guidelines 64.7% 78.6% 67.7% 64.9% 70.2% 0.056
National/international guidelines 71.3% 66.4% 73.8% 54.1% 68.4% 0.154
Government directives 55.3% 47.9% 69.2% 48.6% 54.3% 0.033
Inadequate resources 19.3% 22.9% 49.2% 37.8% 27.3% <0.001
Inadequate staff 15.3% 32.1% 44.6% 37.8% 28.3% <0.001
Concerns about overwhelming healthcare system 26.0% 40.7% 41.5% 37.8% 34.9% 0.033
Inadequate PPE 15.3% 22.1% 35.4% 24.3% 21.9% 0.013
Other systems factor 2.0% 5.0% 0.0% 0.0% 2.6% 0.101
PPE, personal protective equipment.
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patient survival and 25.1% (n=108) reported concern 
this would lead to worse patient survival (figure 4) . Most 
participants reported patient survival would be worse 
due to reduced access to standard treatment pathways 
(n=307; 71.4%) and delayed referrals and/or presenta-
tions (n=378; 87.3%).
Impact of COVID-19 on clinician mental health
Mental health was negatively impacted for 52.6% of clini-
cians (43.5% (n=157) reported somewhat worse and 9.1% 
(n=33) reported significantly worse). The percentage of 
clinicians who reported negative health impacts due to 
working as a clinician during the COVID-19 pandemic 
was 61.3% (n=81) in Europe, 54.0% (n=27) in Asia and 
41.7% (n=61) in AUS/NZ.
Likelihood of service delivery changes persisting after 
COVID-19 pandemic
With regard to the likelihood that some of the changes 
to cancer service delivery would continue after the 
COVID-19 pandemic, clinicians overall thought this was 
more likely than not (median 7.0 on 10- point scale when 
10 is extremely likely and 0 not at all likely).
DISCUSSION
This multidisciplinary global survey has identified that 
most oncology clinicians (88.8%) are altering their 
practice as a result of COVID-19. Key findings include 
reduced numbers of patients being reviewed by oncology 
clinicians, increase in telehealth use and concerns this 
Figure 2 Changes to patient management by medical oncologists due to COVID-19. Panel A demonstrates the ways in 
which medical oncologists report altering management in the curative setting and Panel B in the palliative setting.
Figure 3 Changes to patient management by radiation oncologists due to COVID-19. Panel A demonstrates the ways in 
which radiation oncologists report altering management in the curative setting and Panel B in the palliative setting.
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may negatively impact patient outcomes, as well as many 
clinicians being less likely to prescribe cancer- directed 
therapies, including in both palliative and (neo)adjuvant 
settings. Despite the fact that AUS/NZ had relatively low 
COVID-19 case numbers at the time of the survey, when 
compared with Europe, a greater percentage of clinicians 
from this region reported certain healthcare resource 
concerns as factors influencing cancer management.
Our survey results suggest that, for the surveyed group 
alone, 5010 fewer patients/week are being reviewed 
compared with prior to the pandemic. This likely reflects 
a significant reduction in new patients being seen by 
cancer specialists and is congruent with global reports of 
reduced patient referrals and presentations. Data from 
the Netherlands Cancer Registry found new cancer diag-
noses were down to 73% from prior to the COVID-19 
pandemic.19 Modelling studies predict significant cancer- 
related deaths resulting from such diagnostic delays.16 17 
More recent guidelines from ESMO suggest mitigation 
strategies to try to minimise the impact of changes to 
cancer service delivery on indirect COVID-19- related 
mortality.20
While it is not surprising to find telehealth use has 
increased globally, clinicians reported a larger relative 
increase in AUS/NZ compared with Europe, despite much 
lower COVID-19 case numbers. One possible contributor 
to this is the introduction of COVID-19- specific telehealth 
billing codes by the Medical Benefits Schedule in AUS on 
13 March, supporting clinicians to use this where appro-
priate.21 It is postulated that increased telehealth use is 
likely to persist after the pandemic, further necessitating 
ongoing research into concerns held by the quarter of 
clinicians reporting fears that telehealth will lead to worse 
patient survival.
In our study, the reported changes to cancer manage-
ment and service delivery in response to COVID-19 and 
the proportion of clinicians reporting concerns about 
healthcare resources did not always reflect the geographic 
burden of COVID-19. For example, compared with 
Europe, a greater proportion of clinicians in AUS/NZ 
reported concerns about overwhelming the healthcare 
system as a factor in their decision- making. Possible expla-
nations for this incongruence may be that clinicians in 
AUS/NZ answered the survey hypothesising on what they 
‘would do’ if COVID-19 cases were to increase or perhaps 
differences in cultures and attitudes between regions.
There are limitations to our study. First, these results 
rely on clinician recall of service changes; actual changes 
may be very different. Second, with the exception of AUS, 
the number of respondents per country is small and so 
findings are not necessarily representative of all clini-
cians. Due to the relatively small number of respondents 
from individual countries, results are grouped by major 
geographical region. Experiences between countries 
within each region may be vastly different and thus group 
comparisons must be interpreted with caution. Third, 
results are from clinicians’ perspectives and do not provide 
an understanding of the lived experience of the oncology 
patient. A recent survey of 5302 oncology patients in the 
Netherlands during the pandemic found 30% of patients 
Figure 4 Predicted impact of changes to patient management and oncology service delivery.
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reported consequences to their oncology treatment or 
follow- up.22 Fourth, surgeons and radiation oncologists 
are under- represented in our survey responses, likely in 
part due to distribution through predominantly medical 
oncology societies. A certain percentage of responses 
were obtained via snowball sampling, possibly resulting in 
selection bias. Additionally, while results clearly suggest 
increase telehealth use, findings did not delineate 
between phone consultations and video consultations. 
Finally, the nature of the COVID-19 pandemic means 
epidemiological curves look different from one country 
to the next. This means apparent associations drawn 
from the survey results are likely to be time dependent 
and comparisons between geographical regions must be 
interpreted with care.
Our study has identified some key issues that should 
be considered by policymakers and clinicians caring for 
people with cancer during the COVID-19 pandemic era 
and beyond. The reduced number of patients being 
reviewed by oncology clinicians will inevitably result in 
a ‘back- log’ of patients requiring specialist review. In 
addition, delays in referrals, presentation and manage-
ment may result in additional cancer- related mortality. 
Wherever possible, countries should be educating the 
community on cancer- related signs and symptoms and 
encouraging primary care practitioners to continue to 
refer people with suspected cancer to relevant specialists. 
An increase in cancer- related morbidity and mortality 
can be expected to result in increasing demand for palli-
ative care. Planning now for innovative ways to expand 
palliative care services in a manner compatible with 
social distancing requirements is critical. In order to miti-
gate the impact of COVID-19 on cancer management, 
novel modes of delivering systemic therapy must also be 
investigated and expanded where appropriate. These 
include nurse- led home infusions and injection prac-
tices, lengthening treatment schedules and delivering 
oral therapy to patients’ home addresses. Telehealth has 
enabled millions of patients worldwide to continue to 
receive care during the COVID-19 pandemic. However, 
if this initiative is to be continued into the future, patient 
perspectives on telehealth, including video versus phone 
consultations, need to be further studied. It is also critical 
that we fully appraise the potential clinician- perceived 
risks associated with telehealth; to this point a follow- up 
survey is planned. Results from our study are being used 
to form an enquiry into actual service delivery changes in 
AUS, as captured by cancer databases over the period of 
the pandemic, with linkage to death registries in order to 
study the impact of these changes. Finally, the finding that 
the majority of oncology clinicians report negative mental 
health impacts from COVID-19 is consistent with findings 
from the ‘ESMO Resilience Taskforce’ surveys, which 
identified that oncology clinicians reported increased 
rates of distress and burn- out throughout the pandemic 
period.23 The ESMO Resilience Taskforce continues to 
work towards strategies to address these issues.
This multidisciplinary survey of oncology clinicians 
from around the world highlights that people with cancer 
are likely facing many additional challenges as a result 
of the COVID-19 pandemic. Results indicate that fewer 
patients are being seen by specialists, treatment pathways 
are being delayed and altered, a greater proportion of 
consultations are being conducted via non- face- to- face 
modalities and surveyed clinicians report concerns that 
these changes are likely to result in worsened patient 
outcomes. The oncology community must continue to 
work together to anticipate how changes to cancer service 
delivery may affect people with cancer and to mitigate the 
potential negative impact on cancer- related morbidity 
and mortality.
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